Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from MRI gadolinium‐enhancing lesions compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Outcomes at 12 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in participants free from disability worsening compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Overall survival · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Disease-free survival · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Resectability · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Quality of life · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Adverse events · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Complete remission · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Partial reduction · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Recurrence · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Recurrence · patients with non‐muscle invasive bladder cancer
It is very uncertain whether intravesically administered BCG combined with IFN‐α changes recurrence compared with intravesically administered BCG alone (very low certainty).
1 finding from 1 review
Disease‐specific quality of life ‐ not reported · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG combined with IFN‐α showed no clear difference in progression compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
Discontinuation of therapy due to adverse events ‐ not measured · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ not reported · patients with non‐muscle invasive bladder cancer
It is very uncertain whether intravesically administered BCG combined with IFN‐α changes disease‐specific mortality compared with intravesically administered BCG alone (very low certainty).
1 finding from 1 review
Disease‐specific quality of life ‐ not reported · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α may leads to higher time‐to‐recurrence compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review